<DOC>
	<DOC>NCT02285504</DOC>
	<brief_summary>This is an open-label proof-of-concept study designed to evaluate the safety, tolerability, PK, and efficacy of SAGE-547 Injection in adult female patients diagnosed with severe postpartum depression (PPD).</brief_summary>
	<brief_title>Evaluate SAGE-547 in Female Patients With Severe Postpartum Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression, Postpartum</mesh_term>
	<criteria>Adult females, 1845 years old who experienced a Major Depressive Episode in the postpartum period beginning within the first 4 weeks following delivery Patient has ceased lactating, or if still lactating has already fully and permanently weaned their infant; if still actively breastfeeding, patient must agree to cease giving breast milk to their infant prior to study entry Recent history or active clinically significant manifestations of metabolic, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, musculoskeletal, dermatological, urogenital, or eyes, ears, or nose and throat (EENT) disorders Active psychosis Medical history of seizures</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Postpartum depression</keyword>
</DOC>